DE69104615T2 - Diphenylpiperazinderivat. - Google Patents

Diphenylpiperazinderivat.

Info

Publication number
DE69104615T2
DE69104615T2 DE69104615T DE69104615T DE69104615T2 DE 69104615 T2 DE69104615 T2 DE 69104615T2 DE 69104615 T DE69104615 T DE 69104615T DE 69104615 T DE69104615 T DE 69104615T DE 69104615 T2 DE69104615 T2 DE 69104615T2
Authority
DE
Germany
Prior art keywords
formula
compound
myocardial infarction
necrosis
diphenylmethylpiperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69104615T
Other languages
German (de)
English (en)
Other versions
DE69104615D1 (de
Inventor
Kouji Kirinbeer K. K. Takasaki-Shi Gunma-Ken 370-12 Akimoto
Noboru Tokyo 157 Kaneko
Tatsuo Kirinbeer K. K. Takasaki-Shi Gunma-Ken 370-12 Nakajima
Tatsushi Kirinbeer K. K. Takasaki-Shi Gunma-Ken 370-12 Oosawa
Hideo Kirinbeer K. K. Takasaki-Shi Gunma-Ken370-12 Oota
Makoto Suginami-Ku Tokyo 168 Takeishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69104615D1 publication Critical patent/DE69104615D1/de
Publication of DE69104615T2 publication Critical patent/DE69104615T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DE69104615T 1990-07-10 1991-07-10 Diphenylpiperazinderivat. Expired - Lifetime DE69104615T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2182095A JP2651043B2 (ja) 1990-07-10 1990-07-10 ジフェニルメチルピペラジン誘導体
PCT/JP1991/000924 WO1992000962A1 (en) 1990-07-10 1991-07-10 Diphenylmethylpiperazine derivative

Publications (2)

Publication Number Publication Date
DE69104615D1 DE69104615D1 (de) 1994-11-17
DE69104615T2 true DE69104615T2 (de) 1995-03-23

Family

ID=16112265

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69104615T Expired - Lifetime DE69104615T2 (de) 1990-07-10 1991-07-10 Diphenylpiperazinderivat.

Country Status (12)

Country Link
US (1) US5304558A (enExample)
EP (1) EP0541802B1 (enExample)
JP (1) JP2651043B2 (enExample)
CN (1) CN1037840C (enExample)
AT (1) ATE112764T1 (enExample)
AU (1) AU8212591A (enExample)
CA (1) CA2087032C (enExample)
DE (1) DE69104615T2 (enExample)
RU (1) RU2091379C1 (enExample)
TW (1) TW198717B (enExample)
WO (1) WO1992000962A1 (enExample)
ZA (1) ZA915366B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2144669A1 (en) * 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
US5658963A (en) * 1995-02-02 1997-08-19 Bisco, Inc. One-component primer/bonding-resin systems
CA2385996C (en) 1999-09-30 2008-02-12 Noboru Kaneko Anticancer agents
AU2001239469A1 (en) * 2000-03-31 2001-10-08 Pfizer Products Inc. Novel piperazine derivatives
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
AU2002326823B2 (en) * 2001-09-06 2005-12-15 Merck Sharp & Dohme Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
JP5318938B2 (ja) 2011-06-09 2013-10-16 株式会社アエタスファルマ ジフェニルメチルピペラジン誘導体、及びそれを用いた医薬組成物
JP6021616B2 (ja) * 2012-12-04 2016-11-09 株式会社アエタスファルマ ３−ピペラジニル−１−ピペリジニル−プロパン誘導体及びそれを含有してなる医薬組成物
KR102257892B1 (ko) 2014-11-26 2021-05-28 삼성전자주식회사 개선된 ｎｆｃ 안테나 및 그 안테나를 갖는 전자 장치

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR65270B (en) * 1978-10-10 1980-07-31 Fujisawa Pharmaceutical Co Isatin derivatives and processes for the preparation thereof
DE3536797A1 (de) * 1985-10-16 1987-04-16 Studiengesellschaft Kohle Mbh Verfahren zur herstellung von halogen-magnesium-alanat und dessen verwendung
JPS62192381A (ja) * 1986-02-14 1987-08-22 サンド・アクチエンゲゼルシヤフト プリン誘導体類、その製造方法およびそれらを含有する医薬品
NL8700245A (nl) * 1986-02-14 1987-09-01 Sandoz Ag Purinederivaten, werkwijzen voor hun bereiding en geneesmiddelen die deze derivaten bevatten.
US4885300A (en) * 1988-03-03 1989-12-05 Ortho Pharmaceutical Corporation 4-Substituted pyrazolo[3,4-D]pyrimidine derivatives
US5215987A (en) * 1990-04-23 1993-06-01 Ortho Pharmaceutical Corporation Substituted benzhydryl 2-hydroxypropyl piperazine derivatives

Also Published As

Publication number Publication date
WO1992000962A1 (en) 1992-01-23
US5304558A (en) 1994-04-19
CA2087032A1 (en) 1992-01-11
ZA915366B (en) 1992-04-29
EP0541802A4 (en) 1993-05-26
JP2651043B2 (ja) 1997-09-10
AU8212591A (en) 1992-02-04
DE69104615D1 (de) 1994-11-17
ATE112764T1 (de) 1994-10-15
EP0541802B1 (en) 1994-10-12
RU2091379C1 (ru) 1997-09-27
CN1037840C (zh) 1998-03-25
CA2087032C (en) 1999-06-15
TW198717B (enExample) 1993-01-21
JPH0469377A (ja) 1992-03-04
CN1058963A (zh) 1992-02-26
EP0541802A1 (en) 1993-05-19

Similar Documents

Publication Publication Date Title
DE69104615T2 (de) Diphenylpiperazinderivat.
DE69111619T2 (de) 1,4-benzothiazedinderivat.
DD202001A5 (de) Verfahren zur herstellung von aminoaethanolen
DE2365896B2 (de) Derivate des 4-(4-Diphenylmethylenpiperidino)-butan-l-ons und diese enthaltende Arzneimittel
DE3685604T2 (de) 1,7-naphthyridinderivate und diese enthaltende arzneimittel.
DE69004973T2 (de) Piperidine, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel.
DE69522257T2 (de) Piperidin-Derivate und diese enthaltende Antiplättchen-Agents
EP0217372B1 (de) Neue polyoxygenierte Labdan-Derivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Medikamente
DE3031791C2 (enExample)
EP0210342A2 (de) Arzneimittel, enthaltend Pyridinone mit antithrombotischer Wirkung
DE3445339A1 (de) 3,3-disubstituierte 1-(phenylamino)-guanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE68910211T2 (de) Estramustin-ester.
DE69200284T2 (de) Verwendung von 4-(3-trifluormethylphenyl)-1,2,3,6-Tetrahydropyridinderivaten als freie Radikalfänger.
CH643549A5 (de) N-(trimethoxybenzyl)-n'-phenylpiperazine.
DE69815518T2 (de) S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide als 5-ht2 rezeptor antagonist
DE9017900U1 (de) 3,4-Dihydro-1-benzyl-6,7-dimethoxy-α- [di-2-(2,3,4-trimethoxyphenyl)ethyl] aminocarbonyl-isochinolin
DE3212882A1 (de) Piperazinderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE1911464B2 (de) 3,4-Dihydroisochinoline, Verfahren zu ihrer Herstellung und Arzneimittel
DE69010757T2 (de) Phenylalkanolsäureester.
DE1925956B2 (de) 4- [3-(subst- Amino)-2-hydroxypropoxy] -1,2,5thiadiazolverbindungen und ein diese Verbindungen enthaltendes pharmazeutisches Mittel
DE2416491C3 (de) 13.02.74 V.SLVAmerika 442033 Dibenzopyranverbindungen und diese enthaltende Arzneimittel Abbott Laboratories, North Chicago, 111. (V.StA.)
DE69212531T2 (de) Anti-Ulcer Agent
DE69424816T2 (de) N-Benzylpiperazinverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende Zusammensetzungen
DE69520876T2 (de) Gamma-diketonverbindung mit thrombozytenaggregationshemmender wirkung
DE69007045T2 (de) Piperidinderivate, Verfahren zur Herstellung sowie diese enthaltende pharmazeutische Präparate.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition